Journal Article

The histone methyltransferase DOT1L is required for proper DNA damage response, DNA repair, and modulates chemotherapy responsiveness

Johnsen, Steven A., Gaedcke, Jochen, Henck, Jana Maria, Mansour, Wael Yassin, Kitz, Julia, Kosinsky, Robyn Laura, Übelmesser, Nadine, Kramer, Frank, Eggert, Jessica, Najafova, Zeynab, Grade, Marian, Bastians, Holger, Wegwitz, Florian, Spitzner, Melanie, Raul, Sanjay Kumar, Kari, Vijayalakshmi

2019

Overview

Background Disruptor of telomeric silencing 1-like (DOT1L) is a non-SET domain containing methyltransferase known to catalyze mono-, di-, and tri-methylation of histone 3 on lysine 79 (H3K79me). DOT1L-mediated H3K79me has been implicated in chromatin-associated functions including gene transcription, heterochromatin formation, and DNA repair. Recent studies have uncovered a role for DOT1L in the initiation and progression of leukemia and other solid tumors. The development and availability of small molecule inhibitors of DOT1L may provide new and unique therapeutic options for certain types or subgroups of cancer. Methods In this study, we examined the role of DOT1L in DNA double-strand break (DSB) response and repair by depleting DOT1L using siRNA or inhibiting its methyltransferase activity using small molecule inhibitors in colorectal cancer cells. Cells were treated with different agents to induce DNA damage in DOT1L-depleted or -inhibited cells and analyzed for DNA repair efficiency and survival. Further, rectal cancer patient samples were analyzed for H3K79me3 levels in order to determine whether it may serve as a potential marker for personalized therapy. Results Our results indicate that DOT1L is required for a proper DNA damage response following DNA double-strand breaks by regulating the phosphorylation of the variant histone H2AX (γH2AX) and repair via homologous recombination (HR). Importantly, we show that small molecule inhibitors of DOT1L combined with chemotherapeutic agents that are used to treat colorectal cancers show additive effects. Furthermore, examination of H3K79me3 levels in rectal cancer patients demonstrates that lower levels correlate with a poorer prognosis. Conclusions In this study, we conclude that DOT1L plays an important role in an early DNA damage response and repair of DNA double-strand breaks via the HR pathway. Moreover, DOT1L inhibition leads to increased sensitivity to chemotherapeutic agents and PARP inhibition, which further highlights its potential clinical utility. Our results further suggest that H3K79me3 can be useful as a predictive and or prognostic marker for rectal cancer patients.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Biomedical and Life Sciences / Biomedicine / Biotechnology / Cancer / Cancer cells / Cancer epigenetics and diagnostics / Cancer patients / Cancer research / Cancer therapies / Cancer treatment / Cell Line, Tumor / Chemotherapy / Chromatin / Colorectal cancer / Colorectal carcinoma / Defects / Deoxyribonucleic acid / DNA / DNA Breaks, Double-Stranded - drug effects / DNA damage / DNA double-strand breaks / DNA methylation / DNA repair / DOT1L / Double-strand break repair / Drug Resistance, Neoplasm / Epigenesis, Genetic / Gene Function / Genes / Genetic research / H3K79me / HCT116 Cells / Health aspects / Heterochromatin / Histone H2A / Histone methyltransferase / Histone-Lysine N-Methyltransferase / Histones / Histones - metabolism / Homologous recombination / Human Genetics / Humans / Kinases / Leukemia / Lysine / Medical prognosis / Metastasis / Methylation / Methyltransferases / Methyltransferases - antagonists & inhibitors / Methyltransferases - genetics / Methyltransferases - metabolism / Patients / Phosphorylation / Poly(ADP-ribose) polymerase / Prognosis / Recombinational DNA Repair / Rectal Neoplasms - metabolism / Rectum / RNA, Small Interfering - pharmacology / siRNA / Small Molecule Libraries - pharmacology / Solid tumors / Studies / Transcription / Transcription (Genetics) / Transferases / Tumors / γH2AX